AstraZeneca\'s Imfinzi immunotherapy combo fails to show benefit in lung cancer

AstraZeneca's Imfinzi immunotherapy combo fails to show benefit in lung cancer

AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent Phase 3 trial in the treatment of previously untreated patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).

The results of the study showed that the combo, as well as Imfinzi alone, did not improve overall survival compared to standard of care chemotherapy in patients whose tumours express PD-L1 on more than 25% of their cancer cells.

read more

More From BioPortfolio on "AstraZeneca's Imfinzi immunotherapy combo fails to show benefit in lung cancer"